Generation and immunological evaluation of SARS-CoV-2 membrane protein virus-like particles.

Publication date: Jul 17, 2026

The emergence of the SARS-CoV-2 pandemic led to the spread of highly transmissible variants, such as the Delta variant, which originated in India, underscoring the urgent need to develop new antivirals, therapeutics, and vaccines. In our previous study, we showed that Membrane-Envelope Virus-like Particles exhibit antigenicity and neutralization activity. Hence, our present study was conducted to evaluate whether the M protein alone can form VLPs that elicit an immune response. Using computational methods, we identified key interacting residues in M-protein that contribute to VLP formation and interact with other structural proteins, including Spike (S), Nucleocapsid (N), and Envelope (E). The SARS-CoV-2-M protein was expressed in Sf-21 insect cells, and the resulting VLPs were purified, analyzed for shape and size, and characterized using DLS, FESEM, and TEM. The purified VLPs were injected into BALB/c mice to evaluate their immune response compared with uninfected controls. The biophysical analysis confirms that the particles are round and have a size of ~ 180-200 nm. The serum levels of IgG, IgM, and IgA were found to be higher in immunized mice than in uninfected mice. Further qRT-PCR analysis demonstrated the levels of IFN-γ, IL-2, and IL-12, indicating a TH1-biased immune response against the M protein. Our study demonstrates that the highly conserved M protein can self-assemble into VLPs and elicit humoral and cellular immune response. Furthermore, our study indicates that while M-protein VLPs elicit significant antibodies and cytokine responses, they do not induce detectable neutralizing activity when given alone.

Open Access PDF

Concepts Keywords
Immune response
Membrane protein
SARS-CoV-2
TEM
Virus-like particles

Semantics

Type Source Name
drug DRUGBANK Tretamine
pathway REACTOME Reproduction
disease MESH included
drug DRUGBANK L-Aspartic Acid
drug DRUGBANK Coenzyme M
disease MESH Middle East respiratory syndrome
drug DRUGBANK Phosphate ion
pathway KEGG Virion
pathway REACTOME Release
drug DRUGBANK Methylergometrine
disease MESH FBS
drug DRUGBANK Glycerin
drug DRUGBANK Sucrose
drug DRUGBANK Flunarizine
drug DRUGBANK Tromethamine
drug DRUGBANK Copper
drug DRUGBANK Aluminum hydroxide
drug DRUGBANK L-Leucine
drug DRUGBANK Biotin
drug DRUGBANK Isopropyl Alcohol
drug DRUGBANK Ethanol
drug DRUGBANK Water
drug DRUGBANK Glutamic Acid
drug DRUGBANK L-Tyrosine
drug DRUGBANK L-Lysine
drug DRUGBANK L-Asparagine
drug DRUGBANK Sodium lauryl sulfate
disease MESH SDS
drug DRUGBANK Aspartame
disease MESH PBS
disease MESH infection
disease MESH inflammation
drug DRUGBANK Albendazole
pathway REACTOME Budding
disease MESH SARS CoV 2 infection
disease MESH Severe Acute Respiratory Syndrome
disease MESH Dis
disease MESH CAM
drug DRUGBANK (S)-Des-Me-Ampa
disease MESH ISS
disease MESH AAAS
drug DRUGBANK Prednisolone
disease MESH Hepatitis
drug DRUGBANK L-Cysteine
drug DRUGBANK Papain
disease MESH cytokine storm
disease MESH infectious diseases
drug DRUGBANK Amino acids

Original Article

(Visited 4 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *